Abstract
This study aimed to determine whether progress in developing bleeding risk estimation tools for patients on oral anticoagulant therapy has been made since 2006 when we last systematically reviewed this topic, and to refresh previously published quantitative evaluations of the clinical prediction rules (CPRs) available for estimating bleeding risk in patients on oral anticoagulant therapy. A systematic review of English language literature published since December 2006 was conducted when our previous systematic review ended. Studies were analyzed for predictive performance using likelihood ratios. Six studies detailed CPRs used to assess risk of bleeding prior to commencing warfarin therapy, four of which were included in the analysis. Three studies evaluated new CPRs (“RIETE” and “HAS-BLED”). One of the studies was a further validation of the modified outpatient bleeding risk index (mOBRI) in patients with atrial fibrillation. Individual trial and pooled analyses using likelihood ratios for mOBRI and HAS-BLED showed they have weak predictive accuracy. A RIETE score of 0 point was moderately predictive of the absence of major bleeding. None of the CPRs exhibited sufficient predictive accuracy or had sufficient validation to be recommended for routine use in practice. None of the available CPRs exhibit sufficient predictive accuracy or have trials evaluating the impact of their use on patient outcomes. Hence, no existing oral anticoagulation major bleeding CPR can be recommended for routine use in practice at present.
Similar content being viewed by others
References
Ansell J, Hirsh J, Hylek E et al (2008) The pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:160S–198S
Connolly SJ, Ezekowitz MD, Yusuk S, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med 361. 10.1056/NEJMoa0905561
Schulman S, Kearon C, Kakkar AK, et al. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER). N Engl J Med 361. 10.1056/NEJMoa0906598
Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial (RE-NOVATE). Lancet 370:949–956
Turpie AGG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680
Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807–815
Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95(3):315–328
ROCKET AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation rationale and design of the ROCKET AF study. Am Heart J 159(3):340–347.e.1
Gasse C, Hollowell J, Meier CR et al (2005) Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 94(3):537–543
Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689–2696
Dahri K, Loewen P (2007) The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 98:980–987
The Cochrane Library. Cochrane reviewers’ handbook 5.0.2. 2009; available at http://www.cochrane-handbook.org. Accessed 12 December 2010
Liberati A, Altman DG, Tetzlaff D et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W-65–W-94
Sportif III (2003) Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691–1698
Sportif V (2005) Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 293:690–698
Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694
Ingui BJ, Rogers MAM (2001) Searching for clinical prediction rules in Medline. J Am Med Inform Assoc 8(4):391–397
Laupacis A, Sekar N, Stiell IG (1997) Clinical prediction rules: a review and suggested modifications of methodological standards. JAMA 277(6):488–494
McGinn TG, Guyatt GH, Wyer PC et al (2000) Users’ guides to the medical literature XXII: how to use articles about clinical decision rules. JAMA 284(1):79–84
Peirce JC, Cornell RG (1993) Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Making 13(2):141–151
Deeks JJ, Altman DG (2004) Diagnostic tests 4: likelihood ratios. BMJ 329(7458):168–169
Greenhalgh T (1997) How to read a paper: papers that report diagnostic or screening tests. BMJ 315:540–543
Sackett DL, Haynes RB, Guyatt GH, Tugwell P (1991) Clinical epidemiology—a basic science for clinical medicine. London, Little Brown 51–68
Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928–935
Jaeschke R, Guyatt G, Sackett DL (1994) Users’ guides to the medical literature: III. How to use an article about a diagnostic test: A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 271(5):389–391
Jaeschke R, Guyatt GH, Sackett DL (1994) User’s guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? JAMA 271(9):703–707
van der Meer FJM, Rosendaal FR, Vandenbroucke JP et al (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76(1):12–16
Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 138(5):1093–1100
Lip GYH, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 57:173–180
Airaksinen KEJ, Suurmunne H, Porela P et al (2010) Usefulness of outpatient bleeding risk index to predict bleeding complications in patients with long-term oral anticoagulation undergoing coronary stenting. Am J Cardiol 106:175–179
Ruiz-Giminez N et al (2008) Predictive variables for major bleeding events in patients presenting with document acute venous thromboembolism: findings from the RIETE registry. Thromb Haemost 100:26–31
Wess ML, Schauer DP, Johnston JA et al (2007) Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J Gen Intern Med 23(4):411–417
Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87(2):144–152
Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105(2):91–99
Aspinall SL, DeSanzo BE, Trilli LE et al (2005) Bleeding risk index in an anticoagulation clinic: assessment by indication and implications for care. J Gen Intern Med 20(11):1008–1013
Wells PS, Forgie MA, Simms M et al (2003) The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163(8):917–920
Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke. JAMA 285:2864–2870
Ohman EM, Granger CB, Harrington RA, Lee KL (2000) Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 284:876–878
Harrell E, Califf R, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247:2543–2546
Canadian Cardiovascular Society (2010) Canadian Cardiovascular Society 2010 Atrial Fibrillation Guidelines. Available at http://www.ccsguidelineprograms.ca/index.php?option=com_content&view=article&id=111&Itemid=66. Accessed 12 December 2010
The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31:2369–2429. doi:10.1093/eurheartj/ehq278
Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA (1994) Patient preferences for stroke outcomes. Stroke 25:1721–1725
Devereaux PJ, Anderson DR, Gardner MJ et al (2001) Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J 323:1218–1222
Palareti G, Cosmi B (2009) Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost 102:268–278
Conflicts of interest
No funding was provided to assist in the preparation of the manuscript. The authors have no potential conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Loewen, P., Dahri, K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol 90, 1191–1200 (2011). https://doi.org/10.1007/s00277-011-1267-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-011-1267-3